Q-omics provides the consensus-scored SRGAP2C profile across patient tissues and cancer cell-line models. SRGAP2C expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, SRGAP2C is differentially expressed in 13, with the highest sampling consensus in HNSC. Additionally, SRGAP2C RNA expression shows 19,907 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight KIRP, HNSC, and UVM as cancer lineages where SRGAP2C shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SRGAP2C — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SRGAP2C survival associations across molecular data types. SRGAP2C RNA expression shows survival associations in the most cancer types (25), followed by mutation status (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SRGAP2C RNA expression–survival associations across cancer types. High SRGAP2C expression shows unfavorable associations in KIRP, ACC, UVM, BLCA, LIHC and KICH. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for SRGAP2C RNA expression.
This table summarizes SRGAP2C tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for SRGAP2C. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SRGAP2C shows lower tumor expression in KIRC, KICH, LUAD and LUSC and higher tumor expression in HNSC and LIHC. The HNSC box plot shows higher SRGAP2C RNA expression in tumor versus normal tissue (log2 FC = +0.694, t-test p < 0.001).
This table shows molecular features associated with SRGAP2C in patient tissues and cancer cell lines. In patient samples, SRGAP2C shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, SRGAP2C RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BREAST.
